AI Summary & Key Takeaways
AI InsightThe difference inatypical chemokine receptor allele frequencies betweenhepatitis virus-infected patients and the control groupwas not significant (p=1.00, OR=0.972, 95% CI=0.589-1.603).Conclusion: Our result indicates that atypical chemokinereceptor polymorphism (rs12075) does not affectsusceptibility to hepatitis virus.
📌 3 Key Takeaways
Abstract
Background: Hepatitis virus has infected 130 to150 million individuals globally. Atypical chemokinereceptor has become focus of research because ofits diverse roles in different diseases. However, little isknown regarding the association of atypical chemokinereceptor polymorphism with susceptibility to hepatitisvirus.Aims: To determine the association of an atypicalchemokine receptor polymorphism (rsl2075) withhepatitis virus susceptibility.Study Design: Case-control study.Methods: We collected blood samples from 231 patientsinfected with hepatitis virus and 239 blood donorsas control subjects. Genotyping of atypical chemokinereceptor was performed using '-nuclease assay withTaqMan-minor groove binding probes. Comparisonsbetween hepatitis virus-infected patients and controlsubjects were assessed using Fisher's exact test.Results: The genotype frequencies of *A/F *A,FY*A/FY*B and FY*B/FY*B were 86.1%, 13.9% and0% in the patient group, and 86.2%, 13.4% and 0.4% inthe control group, respectively. The difference in atypicalchemokine receptor genotype frequencies betweenhepatitis virus-infected patients and control groupwas not significant (p=1.00, OR=1.004, 95% CI=0.594-1.695). FY*A and FY*B allele frequencies were 93.1%and 6.9% in the patient group, and 92.9% and 7.1%in the control group, respectively. The difference inatypical chemokine receptor allele frequencies betweenhepatitis virus-infected patients and the control groupwas not significant (p=1.00, OR=0.972, 95% CI=0.589-1.603).Conclusion: Our result indicates that atypical chemokinereceptor polymorphism (rs12075) does not affectsusceptibility to hepatitis virus.